Vyas Tungaturti is a seasoned M&A operator and advisor specializing in large-scale mergers, acquisitions, and private equity due diligence. His experience spans integration and divestiture office leadership, complex cross-border transactions, and the application of AI and machine learning to deal execution. Founder of CorpDev.Org and builder of Kai, an AI due-diligence platform for deal teams, Vyas writes on deal intelligence, value creation, and how AI is reshaping M&A and PE workflows.
TL;DR
Barrick Gold, the world's second-largest gold producer, is signaling M&A readiness to increase its copper exposure and North American footprint. This strategic pivot is driven by surging...
TL;DR
Investor panic over agentic AI's threat to traditional software has triggered a sharp selloff in SaaS stocks, dubbed the "SaaSpocalypse." While public investors fear pricing power...
TL;DR
Humana Inc. is in advanced talks to acquire Sarasota-based primary care network MaxHealth for nearly $1 billion. The deal would bolster Humana's footprint in the critical Florida Medicare...
TL;DR
UK asset manager Schroders has agreed to a £9.9 billion ($13.5 billion) takeover by US-based Nuveen, a subsidiary of TIAA. The deal values Schroders at 612p per share, creating a combined...
TL;DR
Warner Bros. Discovery (WBD) is undergoing a formal auction process for its studio and streaming assets, attracting bids from Paramount Skydance and Netflix. Paramount Skydance's latest offer...
TL;DR
Gail Slater, the DOJ's assistant attorney general for antitrust, departed on February 12, 2026, amid reported clashes with Trump administration officials, including Attorney General Pam Bondi,...
T-Mobile US Inc. continues to scout fiber acquisitions to bolster its fixed wireless and broadband portfolio, but executives emphasize deals must meet strict valuation thresholds in a market flush...
TL;DR
Blackstone's private wealth fund delivered a 20% return in 2025, driven by valuation uplifts in its stakes in SpaceX and OpenAI, which reached $350 billion and $157 billion respectively. These...
TL;DR
Eli Lilly announced its acquisition of Orna Therapeutics for up to $2.4 billion in cash on February 9, 2026, gaining access to Orna's circular RNA platform for in vivo cell engineering. The...
TL;DR
Japan's government has clarified that companies can reject unsolicited takeover bids, a stance to be formalized by May 2026 in an updated corporate takeover code. This policy shift, driven by...
